Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Mediar Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3rd Formulation & Drug Delivery USA

              Participation Not Confirmed

              Update your events

              Distributed Bio Partners With Mediar Therapeutics, Inc.

              Contact the Supplier

              Lead Product(s): Neutralizing antibodies

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Distributed Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 03, 2020

              Details:

              Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.

              Axonis Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3rd Formulation & Drug Delivery USA

              Participation Not Confirmed

              Update your events

              AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

              Contact the Supplier

              Lead Product(s): KCC2

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kerry Murphy

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing May 28, 2020

              Details:

              The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.

              PharmaCompass__DigitalAd